In May, the company said it had raised $1 million in a pre-Series A round, led by 3one4 Capital. The company said its flagship Online Diabetes Reversal Program has resulted in more than 95% patients showing HbA1c (three-month average blood sugar readings) reduction of more than 10% and more than 90% patients with completely stopped or reduced medications. “We are really impressed at the customer stickiness around Breathe’s product and believe that the company has tremendous potential in scaling up this digital-led approach not just with diabetes but with any other conditions,” said Radhika Ananth, vice president, Accel, who focuses on early-stage investments in healthcare and consumer technologies companies at the firm.